PTPRO

Across TCGA pan-cancer cohorts, PTPRO mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PTPRO data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PTPRO mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PTPRO expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, HNSC, and PDAC are the cancer types where PTPRO mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.957	0.608	<.001	32	view →
HNSC	DFS	Quartile	IV	0.505	0.885	.026	4	view →
PDAC	DFS	Median	All	0.874	0.428	.031	3	view →
LSCC	OS	Median	All	0.674	1.000	.021	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PTPRO–CCRCC (DFS)

Open the CCRCC breakdown →